Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 167 for:    trisomy21 NOT prenatal

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00570128
Recruitment Status : Completed
First Posted : December 10, 2007
Last Update Posted : August 6, 2009
Sponsor:
Collaborator:
Pfizer
Information provided by:
Eisai Inc.

Tracking Information
First Submitted Date  ICMJE December 6, 2007
First Posted Date  ICMJE December 10, 2007
Last Update Posted Date August 6, 2009
Study Start Date  ICMJE December 2007
Actual Primary Completion Date September 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 8, 2008)
Vineland-II Adaptive Behavior Scale (VABS-II); Parent/Caregiver Rating Form (PCRF) [ Time Frame: Screen, Baseline, Week 4 and Week 10 or Early Termination. ]
Original Primary Outcome Measures  ICMJE
 (submitted: December 7, 2007)
Vineland-II Adaptive Behavior Scale (VABS-II); Parent/Caregiver Rating Form (PCRF) [ Time Frame: Screen, Baseline, Week 24 and Week 10 or Early Termination ]
Change History Complete list of historical versions of study NCT00570128 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 8, 2008)
The Test of Verbal Expression and Reasoning (TOVER); Population PK (drug levels in the body), PD (drug effects) and safety will also be assessed. [ Time Frame: Baseline, Week 4 and Week 10 or Early Termination. ]
Original Secondary Outcome Measures  ICMJE
 (submitted: December 7, 2007)
The Test of Verbal Expression and Reasoning (TOVER). Population PK (drug levels in the body), PD (drug effects) and safety will also be assessed. [ Time Frame: Screen, Baseline, Week 24 and Week 10 or Early Termination ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
Official Title  ICMJE A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome
Brief Summary The purpose of this study is to determine whether donepezil HCl is effective and safe in improving cognitive dysfunction exhibited by children and adolescents with Down syndrome. Effectiveness will be measured by rating communication, daily living skills, and social skills and relationships in subjects aged 10 to 17.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Down Syndrome
Intervention  ICMJE
  • Drug: Donepezil hydrochloride
    Oral liquid.
    Other Name: Aricept
  • Drug: Placebo
    Oral liquid.
Study Arms  ICMJE
  • Active Comparator: 1
    Intervention: Drug: Donepezil hydrochloride
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: December 7, 2007)
150
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 2008
Actual Primary Completion Date September 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Ages 10 to 17 years old, weight more than or equal to 20kg
  • Male and female
  • VABS-II/PCRF standard composite score >55
  • Diagnosis of DS (trisomy 21) documented by chromosomal analysis (karyotyping). If such documentation is not available at screening, karyotyping will be performed with the screening labs and must be documented prior to baseline visit.
  • Naïve to approved or unapproved cholinesterase inhibitors is preferred however, prior use of these medications is allowed, provided that the medication was discontinued at least 3 months prior to screening and that it was not discontinued for lack of tolerability or efficacy or for the sole purpose of enrolling the subject in the study.
  • Subjects residing in the community
  • Must be expected to complete all procedures scheduled during the Screening and Baseline visits including all efficacy and safety parameters.
  • Must speak English and be verbal and able to be understood most of the time and must not use other forms of communication, signs, symbol boards or devices to supplement his/her communication ability
  • Must have a parent or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
  • a Parent or Caregiver must be a constant and reliable informant with sufficient contact with the subject to have detailed knowledge of the subject's adaptive behavior in order to be able to complete the VABS-II/PCRF accurately. The same individual should complete the form at every visit.
  • Should be in good general health with no medical conditions that are considered both clinically significant and unstable
  • Clinical laboratory values within normal limits or abnormalities considered not clinically significant by the investigator and sponsor
  • Stable Type I (insulin-dependent) or Type II diabetes are eligible provided they are monitored regularly prior to and during the study to ensure adequate glucose control (fasting blood glucose < 140mg/dl and glycosylated hemoglobin [hemoglobin A1c] <8% at screening).
  • Thyroid disease also may be included in the study provided they are euthyroid and stable on treatment for at least 3 months prior to screening.
  • History of seizure disorder is allowed provided that subjects are on stable treatment for at least 3 months and have not had a seizure within the past 6 months.
  • Independent in ambulation or ambulatory aided (i.e., walker or cane, wheelchair), vision and hearing (eyeglasses and/ or hearing aid permissible) sufficient for achieving VABS-II/PCRF composite standard scores >55 and for cooperating with examinations and the TOVER.

Exclusion Criteria:

  • Ages <10 or >17 years
  • Active or clinically significant conditions affecting absorption, distribution or metabolism of the study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers or severe lactose intolerance)
  • Known hypersensitivity to piperidine derivatives or cholinesterase inhibitors
  • Currently receiving cholinesterase inhibitors or who have received them in the 3 months prior to screening or with prior use >3 months prior to screening who stopped for lack of efficacy or tolerability
  • No reliable parent or caregiver, or subjects, or caregivers who are unwilling or unable to complete any of the outcome measures and fulfill the requirements of this study
  • Clinically significant obstructive pulmonary disease or asthma untreated or not controlled by treatment within 3 months prior to screening
  • Recent (less than or equal to 2 years) hematologic/oncologic disorders (mild anemia allowed)
  • Evidence of active, clinically significant, and unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease
  • Current DSM-IV-TR diagnosis of Major Depressive Disorder (MDD) or any current primary psychiatric diagnosis other than DS (as per DSM-IV)
  • Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study
  • Unsuitability which includes female subjects who have begun menstruation and are thus of child-bearing potential, who may be sexually active and who are not practicing an effective means of birth control.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 10 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00570128
Other Study ID Numbers  ICMJE E2020-A001-219
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Eisai Medical Services, Eisai Inc.
Study Sponsor  ICMJE Eisai Inc.
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director: Anita Murthy Eisai Inc.
PRS Account Eisai Inc.
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP